NZ593688A - Micrornas that regulate muscle cell proliferation and differentiation - Google Patents

Micrornas that regulate muscle cell proliferation and differentiation

Info

Publication number
NZ593688A
NZ593688A NZ593688A NZ59368806A NZ593688A NZ 593688 A NZ593688 A NZ 593688A NZ 593688 A NZ593688 A NZ 593688A NZ 59368806 A NZ59368806 A NZ 59368806A NZ 593688 A NZ593688 A NZ 593688A
Authority
NZ
New Zealand
Prior art keywords
micrornas
differentiation
cell proliferation
muscle cell
regulate muscle
Prior art date
Application number
NZ593688A
Inventor
Jianfu Chen
Da-Zhi Wang
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Priority to NZ602571A priority Critical patent/NZ602571A/en
Publication of NZ593688A publication Critical patent/NZ593688A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is the use of an effective amount of miR-206 or a vector encoding miR-206 in the manufacture of a medicament for the treatment of muscle injury in a subject.
NZ593688A 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation NZ593688A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ602571A NZ602571A (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74954405P 2005-12-12 2005-12-12
PCT/US2006/047255 WO2007070483A2 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Publications (1)

Publication Number Publication Date
NZ593688A true NZ593688A (en) 2013-01-25

Family

ID=38163464

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ593688A NZ593688A (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation
NZ602571A NZ602571A (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation
NZ569738A NZ569738A (en) 2005-12-12 2006-12-12 MicroRNAs (miRNA) that regulate muscle cell proliferation and differentiation

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ602571A NZ602571A (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation
NZ569738A NZ569738A (en) 2005-12-12 2006-12-12 MicroRNAs (miRNA) that regulate muscle cell proliferation and differentiation

Country Status (14)

Country Link
US (3) US8431542B2 (en)
EP (3) EP1969125B1 (en)
JP (3) JP2009519339A (en)
KR (2) KR101485071B1 (en)
CN (2) CN101448942B (en)
AU (1) AU2006326517B2 (en)
BR (1) BRPI0619755A2 (en)
CA (2) CA2634046A1 (en)
DK (1) DK1969125T3 (en)
ES (1) ES2387250T3 (en)
NZ (3) NZ593688A (en)
PL (1) PL1969125T3 (en)
PT (1) PT1969125E (en)
WO (1) WO2007070483A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072764B2 (en) 2005-12-12 2015-07-07 The University Of North Carolina At Chapel Hill MicroRNAs that regulate muscle cell proliferation and differentiation

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592384B2 (en) 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
EP2171078B1 (en) 2007-06-29 2016-08-10 Boston Biomedical, Inc. Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells
JP5587777B2 (en) 2007-07-31 2014-09-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム MicroRNA family modulating fibrosis and uses thereof
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
WO2009105759A2 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
JP5689413B2 (en) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 5 'triphosphate oligonucleotide having blunt ends and uses thereof
AU2009257663B2 (en) 2008-06-09 2014-06-26 New York Medical College Compositions comprising cardiac stem cells overexpressing specific microRNA and methods of their use in repairing damaged myocardium
GB0811715D0 (en) * 2008-06-26 2008-07-30 Angeletti P Ist Richerche Bio Therapeutic agents
NZ594365A (en) 2009-02-04 2013-03-28 Univ Texas Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
JP5883381B2 (en) 2009-05-05 2016-03-15 ミラゲン セラピューティクス，インコーポレイテッド Lipophilic polynucleotide conjugate
EP2435570A1 (en) * 2009-05-25 2012-04-04 Carola Ponzetto Differentiation therapy for sarcomas
EP2540829B1 (en) * 2010-02-26 2015-11-25 Lsip, Llc Marker for detection of myogenic diseases, and method for detection of the diseases using same
CA2795430A1 (en) * 2010-04-08 2011-10-13 Kyoto Prefectural Public University Corporation Method for detecting rhabdomyosarcoma using sample derived from body fluid
CA2804791C (en) 2010-07-08 2019-07-30 Duke University Direct reprogramming of cells to cardiac myocyte fate
KR101235256B1 (en) * 2010-09-13 2013-02-21 서울대학교산학협력단 Treatment of Neurodegenerative Diseases by Targeting a miRNA
CA2817002C (en) * 2010-11-05 2019-01-15 Miragen Therapeutics Base modified oligonucleotides
WO2012065024A1 (en) * 2010-11-11 2012-05-18 University Of Miami Compositions, cells, kits and methods for autologous stem cell therapy
AR084319A1 (en) 2010-12-15 2013-05-08 Miragen Therapeutics MicroRNA INHIBITORS (miRNA OR miR) THAT INCLUDE BLOCKED NUCLEOTIDES
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2707485B1 (en) 2011-05-09 2016-12-14 The University Court of The University Of Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
CN103764173A (en) * 2011-07-01 2014-04-30 得克萨斯***大学董事会 Compositions and methods for treating skeletal myopathy
US20140259192A1 (en) * 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
CA2844577A1 (en) * 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
US9428749B2 (en) * 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
KR20150131365A (en) 2013-03-15 2015-11-24 미라젠 세러퓨틱스 인코포레이티드 Bridged Bicyclic Nucleosides
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN103710387B (en) * 2013-12-25 2015-10-14 天津农学院 A kind of method promoting bovine muscle satellite cell in-vitro multiplication
JP6566536B2 (en) * 2014-06-16 2019-08-28 国立大学法人山口大学 Forward primer
CN104498497A (en) * 2014-12-10 2015-04-08 山东农业大学 miRNA related to milk goat mammary epithelial cell apoptosis and application thereof in breeding of milk goats
US10620109B2 (en) 2015-01-14 2020-04-14 Kyoto University Method for selecting skeletal muscle progenitor cell
SG10201906716QA (en) 2015-01-20 2019-08-27 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
CN104877960B (en) * 2015-06-01 2017-09-19 东北农业大学 MiR 2400 remarkably promotes the biological function of bovine muscle satellite cell propagation
CN109312341B (en) * 2016-03-07 2024-02-27 美国政府(由卫生和人类服务部的部长所代表) Micrornas and methods of use thereof
CN105713972A (en) * 2016-03-16 2016-06-29 上海中医药大学 Application of miRNA to preparation of drug-induced heart disease biomarkers
CN106399473B (en) * 2016-08-23 2019-12-06 南京大学 miRNA marker for detecting and evaluating strength training effect or combination thereof and application thereof
WO2018070510A1 (en) * 2016-10-13 2018-04-19 国立研究開発法人国立精神・神経医療研究センター Myogenesis inducing agent
WO2018080658A1 (en) * 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
CN108324946B (en) * 2017-01-20 2022-02-18 上海市东方医院 Application of miRNA708 and/or 301 cluster microRNA in improving cardiac function
CN107096030A (en) * 2017-03-20 2017-08-29 天津农学院 One kind delays amyotrophic method after mouse denervation using the inhibitor of miR 143
US11365412B2 (en) 2017-04-05 2022-06-21 University Of Cincinnati Promotion of cardiomyocyte proliferation and regenerative treatment of the heart by inhibition of microRNA-128
WO2019035690A1 (en) * 2017-08-18 2019-02-21 서울대학교병원 USE OF miR-18b FOR PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE DISEASE AND NEUROMUSCULAR DISEASE
KR102177130B1 (en) * 2017-08-18 2020-11-10 (주)큐라미스 Use of miR-18b for preventing, treating or diagnosing muscular disease and neuromuscular disease
KR20200096610A (en) * 2017-12-08 2020-08-12 유니버시티 오브 워싱톤 Methods and compositions for detecting and promoting cardiolipin remodeling and cardiomyocyte maturation and related methods for treating mitochondrial dysfunction
EP3765610A4 (en) * 2018-03-14 2022-01-19 Beth Israel Deaconess Medical Center Micro-rna and obesity
CN108690846A (en) * 2018-04-17 2018-10-23 上海大学 Inhibit the application of MiR-29b gene expressions
CN108823209B (en) * 2018-07-18 2021-04-09 华中农业大学 Skeletal muscle specific promoter and application
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
CN111041052B (en) * 2019-12-30 2021-05-28 嘉兴学院 Application of mir-206 in inhibiting triglyceride generation in pig fat cells and lean pig breeding
KR20220149590A (en) * 2020-03-02 2022-11-08 테나야 테라퓨틱스, 인코포레이티드 Gene vector control by cardiomyocyte-expressed microRNA
EP4127175A2 (en) 2020-04-02 2023-02-08 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
CN112266912A (en) * 2020-10-22 2021-01-26 上海大学 gRNA of target miR-29b, AAV8-CRISPR/Cas9 system and application thereof
WO2023034966A1 (en) * 2021-09-03 2023-03-09 The University Of North Carolina At Chapel Hill Compositions and methods of using the same for treating disorders associated with thymosin βeta 4
CN114480672B (en) * 2022-02-22 2023-08-15 青岛农业大学 Method for screening high-yield carnitine-producing black cows through miR-145
CN114748497A (en) * 2022-04-27 2022-07-15 广州市妇女儿童医疗中心 miRNA molecule miR-206 for regulating uterine muscle contraction and application thereof
CN115181722B (en) * 2022-08-30 2024-06-11 江苏农牧科技职业学院 In-vitro separation and culture method of goose skeletal muscle satellite cells
CN117511884B (en) * 2023-12-06 2024-06-11 中国农业科学院兰州畜牧与兽药研究所 Application of RTL1 in inhibiting differentiation of yak myoblasts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
EP1592791A2 (en) * 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
SE0300500L (en) * 2003-02-26 2003-11-18 Scania Cv Publ Power transmission with a gearshift different from a main gear
US8173611B2 (en) * 2004-11-12 2012-05-08 Asuragen Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US8592384B2 (en) * 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
JP2009519339A (en) 2005-12-12 2009-05-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル MicroRNAs that regulate myocyte proliferation and differentiation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072764B2 (en) 2005-12-12 2015-07-07 The University Of North Carolina At Chapel Hill MicroRNAs that regulate muscle cell proliferation and differentiation

Also Published As

Publication number Publication date
BRPI0619755A2 (en) 2011-10-18
JP2009519339A (en) 2009-05-14
KR20140130562A (en) 2014-11-10
EP1969125A4 (en) 2010-10-20
PL1969125T3 (en) 2012-11-30
WO2007070483A9 (en) 2011-06-16
NZ602571A (en) 2014-03-28
WO2007070483A2 (en) 2007-06-21
JP5796027B2 (en) 2015-10-21
US20130225658A1 (en) 2013-08-29
US9072764B2 (en) 2015-07-07
PT1969125E (en) 2012-08-16
DK1969125T3 (en) 2012-07-23
KR20080080177A (en) 2008-09-02
EP2671949A1 (en) 2013-12-11
WO2007070483A3 (en) 2008-07-24
CA2634046A1 (en) 2007-06-21
JP5740460B2 (en) 2015-06-24
US20100292297A1 (en) 2010-11-18
ES2387250T3 (en) 2012-09-19
NZ569738A (en) 2012-03-30
EP1969125A2 (en) 2008-09-17
AU2006326517A1 (en) 2007-06-21
AU2006326517B2 (en) 2013-02-21
US8431542B2 (en) 2013-04-30
CA2903764A1 (en) 2007-06-21
CN101448942A (en) 2009-06-03
US20130225665A1 (en) 2013-08-29
EP1969125B1 (en) 2012-06-13
JP2014094943A (en) 2014-05-22
CN104027818A (en) 2014-09-10
EP2497827A1 (en) 2012-09-12
KR101485071B1 (en) 2015-01-26
JP2013126996A (en) 2013-06-27
CN101448942B (en) 2014-04-23

Similar Documents

Publication Publication Date Title
NZ593688A (en) Micrornas that regulate muscle cell proliferation and differentiation
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EP2650002A4 (en) Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
SMT201600182B (en) LIGANDI SIGMA FOR USE IN PREVENTION AND / OR IN THE TREATMENT OF POST-OPERATIVE PAIN
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
MY172012A (en) Use of dpp iv inhibitors
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
SG146451A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
MX2010001449A (en) Bupropion hydrobromide and therapeutic applications.
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
UA104714C2 (en) Isolated polynucleotide brachyspira hyodysenteriae encoding polypeptide and use thereof
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
HK1141436A1 (en) Axomadol for treating pain from arthritis
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
AU318091S (en) Abdominal exercise apparatus
MX2010003615A (en) Treatment of neurological disorders.
UA29731U (en) Zubkova and samosiuk method for treating patients with non-severe craniocerebral injury
UA29775U (en) Kushnirchuk's technique for umbilicus formation
UA61499U (en) massage mat
AU313911S (en) Device for treating muscles
UA33583U (en) Zubkova- samosiuk's method for treatment of patients with cochleovestibular disturbances as result of easy craniocerebral trauma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 DEC 2013 BY CPA GLOBAL

Effective date: 20130829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 DEC 2016 BY CPA GLOBAL

Effective date: 20131212

LAPS Patent lapsed